Genetic Cardiomyopathies Market Size & Share, by Disease Type (Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy, Dilated Cardiomyopathy); Route of Administration (Oral, Typical); Drug Type (Cardiac Glycosides, Antiarrhythmics, Anti-Hypertensives, Anticoagulants); End User (Hospitals, Clinics, Ambulatory Service)-Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5386
  • Published Date: Nov 21, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024 - 2036

Genetic Cardiomyopathies Market size is estimated to reach USD 7 Billion by the end of 2036, growing at a CAGR of 13% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of genetic cardiomyopathies was USD 2 Billion. The growth of the market can be attributed to the increasing instances of genetic cardiomyopathies. There were over 2 million instances of myocarditis, nearly 1.6 million cases of arrhythmogenic cardiomyopathy, and approximately 4 million cases of other cardiomyopathy worldwide. Genetics has played a significant part in the identification of various cardiomyopathies, and the area of heart failure (HF) genetics is quickly expanding.

In addition to these, factors that are believed to fuel the growth of genetic cardiomyopathies market are the approval of new drugs for effective treatment. The Food and Drug Administration (FDA) granted the novel treatment, known as Camzyos, breakthrough therapy and orphan drug designations in April. Patients with obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association class II-III are eligible for treatment to enhance exercise capacity and symptoms. Patients raved about how it improved their quality of life by reducing symptoms such as palpitations, shortness of breath, leg oedema, and diminished exercise ability. Mavacamten minimizes the likelihood that these patients will require a more substantial treatment, such as septal myectomy, an open heart surgery that eliminates a portion of the thickened septum, or alcohol septal ablation.

Genetic Cardiomyopathies Market Overview
Get more information on this report: Request Free Sample PDF

Genetic Cardiomyopathies Market: Growth Drivers and Challenges

Growth Drivers

  • Growing Need for Early Screening– Unless early screening criteria are satisfied, current guidelines of the American College of Cardiology recommend starting family screening for hypertrophic cardiomyopathy (HCM) after the age of 10 or 12 years. The researchers wanted to see if existing screening guidelines missed early-onset illness. Patients and families benefit from a multidisciplinary approach to clinical genetic screening for cardiomyopathies that includes genetic counselling as well as clinical genetic testing. Patients with hereditary cardiomyopathy can begin guideline-directed medical therapy earlier, increasing their chances of improving predictions and health results.
  • Rising Development in Genetic Testing – Recent developments in sequencing technology have enabled wide genetic testing on an individual patient basis within clinically meaningful timeframes, using exome and genome sequencing. Exome tests sequence the whole protein-coding portion of the genome, which accounts for less than 2% of the genome but contains around 85% of known disease-causing variations, whereas genome sequencing not only includes the exome but also all non-protein-coding DNA. Initially, similar tests were used in clinical research investigations such as the Deciphering Developmental Disorders project, but exome sequencing has lately been used as a clinical diagnostic test. Initially, similar tests were used in clinical research investigations such as the Deciphering Developmental Disorders project, but exome sequencing has lately been used as a clinical diagnostic test.
  • Growing Emergence of Novel Therapies– Since there are complications such as the variability of human pathogenic variations, gene and transcript sizes, and other criteria that affect practicality, a variety of alternative molecular techniques have been created to address these issues in genetic cardiomyopathies. A few of the emerging novel therapies for hypertrophic cardiomyopathy and dilated cardiomyopathy are, exon skipping, siRNA, gern line CRISPR, trans-splicing, SERCA gene therapy, and translational read-through of stop colons. Several decades of research have shed light on the exact nature of genetic pathogenesis in many patients with these conditions, leading to novel discoveries into the molecular pathways by which pathogenic variations cause cardiomyopathies. These advancements raise the promise of new medicines that directly target gene variations or the disease-mediating proximal downstream pathways.


  • Privacy Concerns about the Genetic Information of an Individual- Genetic testing raises moral issues about the privacy and security of an individual's genetic information. Ambiguity regarding how the data has been shared and handled is deterring some individuals from getting them diagnosed and treated. Moreover, the integration of digital health and the use of electronic health records further imposes a threat to the data, as digital security can be easily breached by hackers. Genetic testing entails the collecting of very sensitive personal information, such as a person's genetic code, therefore security should be of utmost importance in this respect.
  • Low Awareness about the Disorder among the Common People
  • High Cost of the Treatment and Diagnosis

Genetic Cardiomyopathies Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 2 Billion

Forecast Year Market Size (2036)

~ USD 7 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Genetic Cardiomyopathies Segmentation

Disease Type (Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy, Dilated Cardiomyopathy)

The dilated cardiomyopathy segment is estimated to hold 60% share of the global genetic cardiomyopathies market in the year 2036. The growth of the segment can be attributed to the increasing prevalence of dilated cardiomyopathy. The most prevalent type of cardiomyopathy is dilated cardiomyopathy. Up to one-third of patients with the condition are inherited from their parents. This type of cardiomyopathy is most common in persons under the age of 50. It affects both the lower and upper chambers of the heart. Moreover, there are several research investigations for studying the dilated cardiomyopathy condition in other animals. The FDA announced External Link Disclaimer in July 2018 that it has begun examining allegations of canine dilated cardiomyopathy (DCM) in dogs consuming particular pet foods. The report was submitted by the FDA in November 2022. Furthermore, the FDA's Centre for Veterinary Medicine (CVM) and the Veterinary Laboratory Investigation and Response Network (Vet-LIRN), are continuing to look into this possible link.

End User (Hospitals, Clinics, Ambulatory Service)

Genetic cardiomyopathies market from the hospital segment is expected to garner a significant share of around 46% in the year 2036. The growth of the segment is majorly expected on account of the rising number of hospital admissions, especially of people suffering from heart conditions. In the previous five years, the number of persons hospitalized in hospitals for heart failure has increased by one-third. Hospital admissions in the UK are also increasing owing to the increasing prevalence of heart failure. It is estimated that over 920,000 people suffer from the illness, which places a bigger strain on the health-care system than all four of the most frequent cancers combined.

Our in-depth analysis of the global genetic cardiomyopathies market includes the following segments:

          Disease Type

  • Hypertrophic Cardiomyopathy
  • Restrictive Cardiomyopathy
  • Dilated Cardiomyopathy

          Route of Administration

  • Oral
  • Typical

          End User

  • Hospitals
  • Clinics
  • Ambulatory Service

          Drug Type

  • Cardiac Glycosides
  • Antiarrhythmics
  • Anti-Hypertensives
  • Anticoagulants

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Genetic Cardiomyopathies Industry- Regional Synopsis

North American Market Forecast

The genetic cardiomyopathies market in North America is projected to be the largest with a share of about 38% by the end of 2036. The growth of the market can be attributed majorly to the rising investment in the research and development of gene therapies. Overall private equity and venture capital investment has increased in North America, with a compound annual growth rate of 18% for life sciences from 2010 to 2021. Over the same period, the average growth rate for gene therapy was 59%. Cell treatment has expanded by 63%. This indicates an increase in investment from around USD 360 million in 2020 to over nearly 70 billion in 2021.

APAC Market Statistics

The Asia Pacific genetic cardiomyopathies market is estimated to be the second largest, registering a share of about 25% by the end of 2036. The growth of the market can be attributed majorly to the growing levels of pollution in the atmosphere in the region. Air pollution has been linked to negative cardiac remodelling in patients with dilated cardiomyopathy. Women appear to be more vulnerable to these impacts. Almost 90% of the Asia-Pacific region's population habitually breathes air deemed unhealthy by the World Health Organization (WHO). Air pollution is responsible for more than 7 million premature deaths worldwide, with the Asia-Pacific area accounting for two-thirds of those mortality.

Research Nester
Genetic Cardiomyopathies Market Region
Get more information on this report: Request Free Sample PDF

Companies Dominating the Genetic Cardiomyopathies Market

    • Becton Dickinson and Company
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis International AG
    • Merck & Co.
    • Teva Pharmaceuticals Industries Ltd.
    • Bristol Myers Squibb Company
    • Mylan N.V.
    • Boston Scientific Corporation
    • Critical Care Diagnostics Inc.
    • Bio-Rad Laboratories Inc.
    • Sanofi S.A
    • Roche Holding AG
    • Astella Pharma

In the News

  • April 2023: Bristol Myers Squibb announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) suggested approval of CAMZYOS® (mavacamten) for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients. The European Commission (EC), which has the competence to approve medicines for the European Union (EU), will now assess the CHMP opinion.
  • July 2023: Novartis AG has revealed that the US Food and Drug Administration (FDA) has authorized a label update for Leqvio® (inclisiran) to allow for earlier usage as an addition to diet and statin therapy in patients with elevated LDL-C who are at increased risk of heart disease1. This patient group comprises patients with comorbidities such as hypertension and diabetes who have not yet experienced their first cardiovascular event.  Leqvio is the first and only small interfering RNA (siRNA) medication to decrease LDL-C, and it was approved by the FDA in December 2021.

Author Credits:  Radhika Pawar

  • Report ID: 5386
  • Published Date: Nov 21, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increasing need for early detection and growing development of gene therapies are the major factors driving the market growth.

The market size of genetic cardiomyopathies is anticipated to attain a CAGR of ~13% over the forecast period, i.e., 2024-2036.

The major players in the market are Novartis International AG, Merck & Co., Teva Pharmaceuticals Industries Ltd., Bristol Myers Squibb Company, Mylan N.V., Boston Scientific Corporation, Critical Care Diagnostics Inc., Bio-Rad Laboratories Inc., Roche Holding AG, AstraZeneca PLC, and Sanofi S.A

The dilated cardiomyopathy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Genetic Cardiomyopathies Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying